Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $40.29 | $23.20 | 135.72% | 58.9M | $2.2B | $16.10$40.45 |
| MASK | 3 E Network Technology Group | $2.69 | $1.45 | 116.94% | 97.1M | $28M | $1.19$100.00 |
| KIDZ | Classover | $3.40 | $1.35 | 65.85% | 78.2M | $2.5M | $2.01$532.50 |
| CNTA | Centessa Pharmaceuticals Plc | $39.97 | $12.39 | 44.91% | 754.7K | $3.7B | $9.60$40.25 |
| WSHP | WeShop | $6.60 | $1.50 | 29.41% | 188.5K | $120M | $5.04$250.00 |
| IMDX | Insight Molecular Diagnostics | $3.20 | $0.65 | 25.49% | 19.5K | $82M | $2.33$8.51 |
| NPT | Texxon | $5.93 | $1.16 | 24.32% | 4.5M | $106M | $3.14$22.38 |
| CRMU | Themes ETF Trust - Leverage Shares 2x Long Crml Daily ETF | $4.97 | $0.97 | 24.30% | 40.5K | - | $3.99$15.25 |
| DWSN | Dawson Geophysical | $3.25 | $0.61 | 23.11% | 360.5K | $82M | $1.08$5.54 |
| AGIO | Agios Pharmaceuticals | $36.03 | $6.42 | 21.68% | 1.8M | $1.7B | $22.24$46.00 |
| BAER | Bridger Aerospace Group | $2.08 | $0.36 | 20.64% | 6.4K | $96M | $1.02$3.44 |
| MODD | Modular Medical | $5.48 | $0.94 | 20.58% | 207.5K | $636M | $3.55$34.50 |
| PASG | Passage Bio | $7.42 | $1.24 | 20.07% | 47.1K | $20M | $5.12$20.00 |
| KSCP | Knightscope | $4.03 | $0.64 | 18.70% | 8.8K | $45M | $2.45$10.14 |
| RMCO | Royalty Management | $2.88 | $0.45 | 18.64% | 38.1K | $37M | $0.91$5.00 |
| ALKS | Alkermes Plc | $35.71 | $5.56 | 18.44% | 5.9M | $5.0B | $25.17$36.32 |
| AURE | Aurelion | $2.10 | $0.31 | 17.32% | 7.3K | $62M | $1.50$14.60 |
| CVKD | Cadrenal Therapeutics | $4.98 | $0.73 | 17.09% | 39.9K | $9.9M | $4.21$19.03 |
| JFU | 9f | $3.70 | $0.52 | 16.35% | 6.7K | $28M | $1.01$9.48 |
| MRVU | Direxion Shares Etf Trust - Daily Mrvl Bull 2x Etf | $31.11 | $4.32 | 16.12% | 35.6K | - | $20.80$35.23 |
| GLBS | Globus Maritime | $2.26 | $0.31 | 16.00% | 412.2K | $42M | $0.99$2.34 |
| TBN | Tamboran Resources | $51.26 | $6.82 | 15.35% | 2.5K | $1.0B | $17.29$51.79 |
| UUUG | Themes ETF Trust - Leverage Shares 2x Long Uuuu Daily ETF | $9.62 | $1.25 | 14.94% | 171.1K | - | $8.18$30.00 |
| MVLL | Graniteshares ETF Trust - GraniteShares 2x Long Mrvl Daily ETF | $23.48 | $2.85 | 13.82% | 678.7K | - | $9.66$32.36 |
Related Articles
Featured Article
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
Cory Renauer|Oct 29, 2024
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.
2 Best Growth Stocks to Buy in April
George Budwell, PhD|Apr 3, 2023
Takeover interest is spurring these two biotech stocks higher.
Wall Street Upgraded This Stock's Price Target After a New Approval: Is It a Buy?
James Halley|Feb 27, 2023
The company's lead therapy was just approved for another indication.
Want to Make Money in Biotech? Do This First
Brian Orelli, PhD and Keith Speights|May 7, 2021
Keeping track of upcoming events is important.
Why Alkermes' Q4 Results Were Better Than They Might Seem
Keith Speights|Feb 11, 2021
The biotech posted a big year-over-year sales decline. But there was a good reason for it.
4 Reasons Agios' Oncology Deal Should Please Investors
Cory Renauer|Dec 22, 2020
Agios' newly revamped business strategy is an extreme departure from the company's original mission, but it's a great deal for shareholders.
2 Mid-Cap Healthcare Stocks to Buy Now
Cory Renauer|Sep 5, 2020
These drugmakers are in the sweet spot to provide market-beating returns.
The Coronavirus Pandemic Will Delay 2020 IPOs
Joe Tenebruso|Mar 15, 2020
COVID-19 and initial public offerings don’t go well together.
Gene Therapy Biotech Passage Bio IPOs
Brian Orelli, PhD|Feb 28, 2020
The clinical-stage biotech raised $216 million.
Is Apellis Pharmaceuticals a Buy?
Maxx Chatsko|Feb 3, 2020
The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.
